false2023Q30001521036--12-310.01252910.0178539http://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#LongTermDebtCurrenthttp://fasb.org/us-gaap/2023#LongTermDebtCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations15.3323833600015210362023-01-012023-09-3000015210362023-10-27xbrli:shares00015210362023-09-30iso4217:USD00015210362022-12-31iso4217:USDxbrli:shares00015210362023-07-012023-09-3000015210362022-07-012022-09-3000015210362022-01-012022-09-300001521036us-gaap:CommonStockMember2022-12-310001521036us-gaap:TreasuryStockCommonMember2022-12-310001521036us-gaap:AdditionalPaidInCapitalMember2022-12-310001521036us-gaap:RetainedEarningsMember2022-12-310001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001521036us-gaap:RetainedEarningsMember2023-01-012023-03-3100015210362023-01-012023-03-310001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001521036us-gaap:CommonStockMember2023-01-012023-03-310001521036us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001521036us-gaap:CommonStockMember2023-03-310001521036us-gaap:TreasuryStockCommonMember2023-03-310001521036us-gaap:AdditionalPaidInCapitalMember2023-03-310001521036us-gaap:RetainedEarningsMember2023-03-310001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100015210362023-03-310001521036us-gaap:RetainedEarningsMember2023-04-012023-06-3000015210362023-04-012023-06-300001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001521036us-gaap:CommonStockMember2023-04-012023-06-300001521036us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001521036us-gaap:CommonStockMember2023-06-300001521036us-gaap:TreasuryStockCommonMember2023-06-300001521036us-gaap:AdditionalPaidInCapitalMember2023-06-300001521036us-gaap:RetainedEarningsMember2023-06-300001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000015210362023-06-300001521036us-gaap:RetainedEarningsMember2023-07-012023-09-300001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001521036us-gaap:CommonStockMember2023-07-012023-09-300001521036us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001521036us-gaap:CommonStockMember2023-09-300001521036us-gaap:TreasuryStockCommonMember2023-09-300001521036us-gaap:AdditionalPaidInCapitalMember2023-09-300001521036us-gaap:RetainedEarningsMember2023-09-300001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001521036us-gaap:CommonStockMember2021-12-310001521036us-gaap:TreasuryStockCommonMember2021-12-310001521036us-gaap:AdditionalPaidInCapitalMember2021-12-310001521036us-gaap:RetainedEarningsMember2021-12-310001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-3100015210362021-12-310001521036us-gaap:RetainedEarningsMember2022-01-012022-03-3100015210362022-01-012022-03-310001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001521036us-gaap:CommonStockMember2022-01-012022-03-310001521036us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001521036us-gaap:CommonStockMember2022-03-310001521036us-gaap:TreasuryStockCommonMember2022-03-310001521036us-gaap:AdditionalPaidInCapitalMember2022-03-310001521036us-gaap:RetainedEarningsMember2022-03-310001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100015210362022-03-310001521036us-gaap:RetainedEarningsMember2022-04-012022-06-3000015210362022-04-012022-06-300001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001521036us-gaap:CommonStockMember2022-04-012022-06-300001521036us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001521036us-gaap:CommonStockMember2022-06-300001521036us-gaap:TreasuryStockCommonMember2022-06-300001521036us-gaap:AdditionalPaidInCapitalMember2022-06-300001521036us-gaap:RetainedEarningsMember2022-06-300001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000015210362022-06-300001521036us-gaap:RetainedEarningsMember2022-07-012022-09-300001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001521036us-gaap:CommonStockMember2022-07-012022-09-300001521036us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001521036us-gaap:CommonStockMember2022-09-300001521036us-gaap:TreasuryStockCommonMember2022-09-300001521036us-gaap:AdditionalPaidInCapitalMember2022-09-300001521036us-gaap:RetainedEarningsMember2022-09-300001521036us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-3000015210362022-09-3000015210362020-02-202020-02-200001521036lnth:ProgenicsMember2020-02-202020-02-20xbrli:pure0001521036lnth:CashPayments2022Memberlnth:ProgenicsMember2020-02-200001521036lnth:ProgenicsMemberlnth:CashPayments2023Member2020-02-200001521036us-gaap:ProductMember2023-07-012023-09-300001521036us-gaap:ProductMember2022-07-012022-09-300001521036us-gaap:ProductMember2023-01-012023-09-300001521036us-gaap:ProductMember2022-01-012022-09-300001521036lnth:LicenseandRoyaltyRevenuesMember2023-07-012023-09-300001521036lnth:LicenseandRoyaltyRevenuesMember2022-07-012022-09-300001521036lnth:LicenseandRoyaltyRevenuesMember2023-01-012023-09-300001521036lnth:LicenseandRoyaltyRevenuesMember2022-01-012022-09-30lnth:productCategory0001521036lnth:PYLARIFYMember2023-07-012023-09-300001521036lnth:PYLARIFYMember2022-07-012022-09-300001521036lnth:PYLARIFYMember2023-01-012023-09-300001521036lnth:PYLARIFYMember2022-01-012022-09-300001521036lnth:OtherRadiopharmaceuticalOncologyMember2023-07-012023-09-300001521036lnth:OtherRadiopharmaceuticalOncologyMember2022-07-012022-09-300001521036lnth:OtherRadiopharmaceuticalOncologyMember2023-01-012023-09-300001521036lnth:OtherRadiopharmaceuticalOncologyMember2022-01-012022-09-300001521036lnth:RadiopharmaceuticalOncologyMember2023-07-012023-09-300001521036lnth:RadiopharmaceuticalOncologyMember2022-07-012022-09-300001521036lnth:RadiopharmaceuticalOncologyMember2023-01-012023-09-300001521036lnth:RadiopharmaceuticalOncologyMember2022-01-012022-09-300001521036lnth:DefinityMember2023-07-012023-09-300001521036lnth:DefinityMember2022-07-012022-09-300001521036lnth:DefinityMember2023-01-012023-09-300001521036lnth:DefinityMember2022-01-012022-09-300001521036lnth:TechneLiteMember2023-07-012023-09-300001521036lnth:TechneLiteMember2022-07-012022-09-300001521036lnth:TechneLiteMember2023-01-012023-09-300001521036lnth:TechneLiteMember2022-01-012022-09-300001521036lnth:OtherPrecisionDiagnosticsMember2023-07-012023-09-300001521036lnth:OtherPrecisionDiagnosticsMember2022-07-012022-09-300001521036lnth:OtherPrecisionDiagnosticsMember2023-01-012023-09-300001521036lnth:OtherPrecisionDiagnosticsMember2022-01-012022-09-300001521036lnth:TotalPrecisionDiagnosticsMember2023-07-012023-09-300001521036lnth:TotalPrecisionDiagnosticsMember2022-07-012022-09-300001521036lnth:TotalPrecisionDiagnosticsMember2023-01-012023-09-300001521036lnth:TotalPrecisionDiagnosticsMember2022-01-012022-09-300001521036lnth:StrategicPartnershipsAndOtherMember2023-07-012023-09-300001521036lnth:StrategicPartnershipsAndOtherMember2022-07-012022-09-300001521036lnth:StrategicPartnershipsAndOtherMember2023-01-012023-09-300001521036lnth:StrategicPartnershipsAndOtherMember2022-01-012022-09-300001521036us-gaap:MoneyMarketFundsMember2023-09-300001521036us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-09-300001521036us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2023-09-300001521036us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2023-09-300001521036us-gaap:FairValueInputsLevel1Member2023-09-300001521036us-gaap:FairValueInputsLevel2Member2023-09-300001521036us-gaap:FairValueInputsLevel3Member2023-09-300001521036us-gaap:MoneyMarketFundsMember2022-12-310001521036us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2022-12-310001521036us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2022-12-310001521036us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2022-12-310001521036us-gaap:FairValueInputsLevel1Member2022-12-310001521036us-gaap:FairValueInputsLevel2Member2022-12-310001521036us-gaap:FairValueInputsLevel3Member2022-12-310001521036lnth:ProgenicsMemberlnth:NetSalesTargetsForAzedraMember2023-09-300001521036lnth:ProgenicsMemberlnth:A1095CommercializationMember2023-09-300001521036lnth:A1404CommercializationMilestoneMemberlnth:ProgenicsMember2023-09-300001521036lnth:ProgenicsMember2023-09-300001521036lnth:ContingentValueRightMemberus-gaap:FairValueInputsLevel3Member2022-12-310001521036lnth:ContingentValueRightMemberus-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:FairValueInputsLevel3Memberlnth:MeasurementInputProbabilityOfSuccessMember2022-12-310001521036lnth:A1095CommercializationMemberus-gaap:FairValueInputsLevel3Member2023-09-300001521036lnth:A1095CommercializationMemberus-gaap:FairValueInputsLevel3Member2022-12-310001521036us-gaap:ValuationTechniqueDiscountedCashFlowMemberlnth:A1095CommercializationMemberus-gaap:FairValueInputsLevel3Memberlnth:MeasurementInputProbabilityOfSuccessMember2023-09-300001521036us-gaap:ValuationTechniqueDiscountedCashFlowMemberlnth:A1095CommercializationMemberus-gaap:FairValueInputsLevel3Memberlnth:MeasurementInputProbabilityOfSuccessMember2022-12-310001521036us-gaap:ValuationTechniqueDiscountedCashFlowMemberlnth:A1095CommercializationMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMember2023-09-300001521036us-gaap:ValuationTechniqueDiscountedCashFlowMemberlnth:A1095CommercializationMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMember2022-12-310001521036lnth:ContingentConsiderationNetSalesTargetsMemberus-gaap:FairValueInputsLevel3Member2023-09-300001521036lnth:ContingentConsiderationNetSalesTargetsMemberus-gaap:FairValueInputsLevel3Member2022-12-310001521036lnth:ContingentConsiderationNetSalesTargetsMemberlnth:MonteCarloSimulationMemberus-gaap:FairValueInputsLevel3Membersrt:MinimumMemberlnth:MeasurementInputProbabilityOfSuccessMember2023-09-300001521036lnth:ContingentConsiderationNetSalesTargetsMembersrt:MaximumMemberlnth:MonteCarloSimulationMemberus-gaap:FairValueInputsLevel3Memberlnth:MeasurementInputProbabilityOfSuccessMember2023-09-300001521036lnth:ContingentConsiderationNetSalesTargetsMemberlnth:MonteCarloSimulationMemberus-gaap:FairValueInputsLevel3Membersrt:MinimumMemberlnth:MeasurementInputProbabilityOfSuccessMember2022-12-310001521036lnth:ContingentConsiderationNetSalesTargetsMembersrt:MaximumMemberlnth:MonteCarloSimulationMemberus-gaap:FairValueInputsLevel3Memberlnth:MeasurementInputProbabilityOfSuccessMember2022-12-310001521036lnth:ContingentConsiderationNetSalesTargetsMemberlnth:MonteCarloSimulationMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMembersrt:MinimumMember2023-09-300001521036lnth:ContingentConsiderationNetSalesTargetsMemberlnth:MonteCarloSimulationMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMembersrt:MinimumMember2022-12-310001521036lnth:ContingentConsiderationNetSalesTargetsMembersrt:MaximumMemberlnth:MonteCarloSimulationMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMember2022-12-310001521036us-gaap:LandMember2023-09-300001521036us-gaap:LandMember2022-12-310001521036us-gaap:BuildingMember2023-09-300001521036us-gaap:BuildingMember2022-12-310001521036lnth:MachineryEquipmentAndFixturesMember2023-09-300001521036lnth:MachineryEquipmentAndFixturesMember2022-12-310001521036us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-09-300001521036us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-12-310001521036us-gaap:ConstructionInProgressMember2023-09-300001521036us-gaap:ConstructionInProgressMember2022-12-3100015210362023-01-012023-06-300001521036us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2023-03-310001521036srt:MinimumMemberus-gaap:TrademarksMember2023-09-300001521036srt:MaximumMemberus-gaap:TrademarksMember2023-09-300001521036us-gaap:TrademarksMember2023-09-300001521036us-gaap:CustomerRelationshipsMembersrt:MinimumMember2023-09-300001521036srt:MaximumMemberus-gaap:CustomerRelationshipsMember2023-09-300001521036us-gaap:CustomerRelationshipsMember2023-09-300001521036lnth:CurrentlyMarketedProductMembersrt:MinimumMember2023-09-300001521036lnth:CurrentlyMarketedProductMember2023-09-300001521036us-gaap:LicensingAgreementsMembersrt:MinimumMember2023-09-300001521036us-gaap:LicensingAgreementsMembersrt:MaximumMember2023-09-300001521036us-gaap:LicensingAgreementsMember2023-09-300001521036us-gaap:DevelopedTechnologyRightsMember2023-09-300001521036srt:MinimumMemberus-gaap:TrademarksMember2022-12-310001521036srt:MaximumMemberus-gaap:TrademarksMember2022-12-310001521036us-gaap:TrademarksMember2022-12-310001521036us-gaap:CustomerRelationshipsMembersrt:MinimumMember2022-12-310001521036srt:MaximumMemberus-gaap:CustomerRelationshipsMember2022-12-310001521036us-gaap:CustomerRelationshipsMember2022-12-310001521036lnth:CurrentlyMarketedProductMembersrt:MinimumMember2022-12-310001521036lnth:CurrentlyMarketedProductMembersrt:MaximumMember2022-12-310001521036lnth:CurrentlyMarketedProductMember2022-12-310001521036us-gaap:LicensingAgreementsMembersrt:MinimumMember2022-12-310001521036us-gaap:LicensingAgreementsMembersrt:MaximumMember2022-12-310001521036us-gaap:LicensingAgreementsMember2022-12-310001521036us-gaap:DevelopedTechnologyRightsMember2022-12-3100015210362023-08-022023-08-020001521036us-gaap:LicensingAgreementsMember2023-08-020001521036us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001521036us-gaap:CostOfSalesMember2023-01-012023-03-310001521036lnth:CerveauTechnologiesIncMember2023-02-012023-02-280001521036lnth:CerveauTechnologiesIncMember2023-05-012023-05-310001521036lnth:A2019TermLoanFacilityMemberus-gaap:LineOfCreditMember2022-12-310001521036lnth:A2019TermLoanFacilityMemberus-gaap:LineOfCreditMember2022-12-012022-12-310001521036lnth:A2019RevolvingFacilityMemberus-gaap:LineOfCreditMember2022-12-310001521036lnth:A2019RevolvingFacilityMemberus-gaap:LineOfCreditMember2022-12-012022-12-310001521036lnth:A2022TermFacilityMemberus-gaap:LineOfCreditMember2022-12-310001521036us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-12-310001521036us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2022-12-012022-12-310001521036lnth:A2019TermLoanFacilityMemberus-gaap:LineOfCreditMember2022-01-012022-09-300001521036us-gaap:RevolvingCreditFacilityMembersrt:MaximumMemberus-gaap:LineOfCreditMember2023-09-300001521036us-gaap:LetterOfCreditMemberus-gaap:LineOfCreditMember2023-09-300001521036us-gaap:BridgeLoanMemberus-gaap:LineOfCreditMember2023-09-300001521036us-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembersrt:MinimumMemberus-gaap:LineOfCreditMember2023-01-012023-09-300001521036us-gaap:RevolvingCreditFacilityMembersrt:MaximumMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:LineOfCreditMember2023-01-012023-09-300001521036us-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMemberus-gaap:LineOfCreditMember2023-01-012023-09-300001521036us-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMemberus-gaap:LineOfCreditMember2023-01-012023-09-300001521036lnth:NetLeverageRatioMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMemberus-gaap:LineOfCreditMember2023-01-012023-09-300001521036lnth:NetLeverageRatioMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMemberus-gaap:LineOfCreditMember2023-01-012023-09-300001521036us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-09-30lnth:financial_covenant0001521036lnth:Q32023ToQ42023Memberlnth:A2022FacilityCovenantsMember2023-01-012023-09-300001521036lnth:A2022FacilityCovenantsMemberlnth:Q12024AndThereafterMember2023-01-012023-09-300001521036us-gaap:ConvertibleDebtMemberlnth:A2625ConvertibleSeniorNotesDue2027Member2022-12-080001521036us-gaap:ConvertibleDebtMember2022-12-082022-12-080001521036us-gaap:ConvertibleDebtMemberlnth:A2625ConvertibleSeniorNotesDue2027Member2022-12-082022-12-080001521036us-gaap:ConvertibleDebtMemberlnth:A2625ConvertibleSeniorNotesDue2027Membersrt:MinimumMember2023-09-300001521036us-gaap:ConvertibleDebtMembersrt:MaximumMemberlnth:A2625ConvertibleSeniorNotesDue2027Member2023-09-300001521036us-gaap:ConvertibleDebtMemberlnth:A2625ConvertibleSeniorNotesDue2027Member2023-09-300001521036us-gaap:ConvertibleDebtMemberlnth:A2625ConvertibleSeniorNotesDue2027Member2023-07-012023-09-300001521036us-gaap:ConvertibleDebtMemberlnth:A2625ConvertibleSeniorNotesDue2027Member2023-01-012023-09-300001521036us-gaap:ConvertibleDebtMemberlnth:A2625ConvertibleSeniorNotesDue2027Member2022-12-052022-12-050001521036us-gaap:ConvertibleDebtMemberlnth:A2625ConvertibleSeniorNotesDue2027Member2022-12-082022-12-310001521036us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2020-03-310001521036us-gaap:InterestRateSwapMember2022-12-022022-12-020001521036us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001521036us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310001521036us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-09-300001521036us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-09-300001521036us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300001521036us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-09-300001521036us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310001521036us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310001521036us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-09-300001521036us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-09-300001521036us-gaap:AccumulatedTranslationAdjustmentMember2022-09-300001521036us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-09-300001521036us-gaap:CostOfSalesMember2023-07-012023-09-300001521036us-gaap:CostOfSalesMember2022-07-012022-09-300001521036us-gaap:CostOfSalesMember2023-01-012023-09-300001521036us-gaap:CostOfSalesMember2022-01-012022-09-300001521036us-gaap:SellingAndMarketingExpenseMember2023-07-012023-09-300001521036us-gaap:SellingAndMarketingExpenseMember2022-07-012022-09-300001521036us-gaap:SellingAndMarketingExpenseMember2023-01-012023-09-300001521036us-gaap:SellingAndMarketingExpenseMember2022-01-012022-09-300001521036us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001521036us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001521036us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001521036us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001521036us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001521036us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001521036us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001521036us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001521036lnth:BedfordMassachusettsMember2022-02-280001521036lnth:BedfordMassachusettsMember2023-09-300001521036lnth:BedfordMassachusettsMember2023-09-010001521036us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001521036us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001521036us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001521036us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001521036us-gaap:RestrictedStockMember2023-07-012023-09-300001521036us-gaap:RestrictedStockMember2022-07-012022-09-300001521036us-gaap:RestrictedStockMember2023-01-012023-09-300001521036us-gaap:RestrictedStockMember2022-01-012022-09-300001521036lnth:CerveauTechnologiesIncMemberlnth:SalesMilestonesMember2023-02-012023-02-280001521036lnth:CerveauTechnologiesIncMemberlnth:ResearchRevenueMilestonesMember2023-02-012023-02-280001521036lnth:POINTBiopharmaMember2022-12-012022-12-310001521036lnth:PNT2002LicenseAgreementMember2022-12-012022-12-310001521036lnth:PNT2002LicenseAgreementMemberlnth:RegulatoryMilestonesMember2022-12-012022-12-310001521036lnth:SalesMilestonesMemberlnth:PNT2002LicenseAgreementMember2022-12-012022-12-310001521036lnth:PNT2003LicenseAgreementMember2022-12-012022-12-310001521036lnth:PNT2003LicenseAgreementMemberlnth:RegulatoryMilestonesMember2022-12-012022-12-310001521036lnth:PNT2003LicenseAgreementMemberlnth:SalesMilestonesMember2022-12-012022-12-310001521036lnth:POINTBiopharmaMember2022-01-012022-12-31lnth:segment0001521036lnth:RobertMarshallMember2023-01-012023-09-300001521036lnth:RobertMarshallMember2023-07-012023-09-300001521036lnth:RobertMarshallMember2023-09-300001521036lnth:AndreaSabensMember2023-01-012023-09-300001521036lnth:AndreaSabensMember2023-07-012023-09-300001521036lnth:AndreaSabensMember2023-09-30

For the transition period from                      to                     

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☑    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☑    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Act)    Yes  ☐    No  ☑

The registrant had 68,489,153 shares of common stock, $0.01 par value, outstanding as of October 27, 2023.

(Unaudited)

(in thousands, except par value)

(Unaudited)

(in thousands, except per share data)

(Unaudited)

(Unaudited)

(Unaudited)

(Unaudited)

(Unaudited)

Unless the context otherwise requires, references to the “Company” and “Lantheus” refer to Lantheus Holdings, Inc. and its direct and indirect wholly-owned subsidiaries; references to “Lantheus Holdings” refer to Lantheus Holdings, Inc. and not to any of its subsidiaries; references to “LMI” refer to Lantheus Medical Imaging, Inc., the direct subsidiary of Lantheus Holdings; references to “Cerveau,” “Lantheus Real Estate,” “Lantheus Two,” “Lantheus Three” and “Progenics” refer to Cerveau Technologies, Inc.; Lantheus MI Real Estate, LLC; Lantheus Two, LLC; Lantheus Three, LLC; and Progenics Pharmaceuticals, Inc., respectively, each a wholly-owned subsidiary of LMI, and references to “EXINI” refer to EXINI Diagnostics AB, a wholly-owned subsidiary of Progenics. Solely for convenience, the Company refers to trademarks, service marks and trade names without the TM, SM and ® symbols. Those references are not intended to indicate, in any way, that the Company will not assert, to the fullest extent permitted under applicable law, its rights to its trademarks, service marks and trade names.

The accompanying unaudited condensed consolidated financial statements include the accounts of Lantheus and have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all of the information and notes required by generally accepted accounting principles in the United States (“U.S. GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement have been included. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ended December 31, 2023 or any future period.

The condensed consolidated balance sheet at December 31, 2022 has been derived from the audited consolidated financial statements at that date but does not include all the information and notes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities Exchange Commission (“SEC”) on February 23, 2023.

On June 19, 2020 (the “Closing Date”), pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of February 20, 2020 (the “Merger Agreement”), by and among Lantheus Holdings, Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus Holdings (“Merger Sub”), and Progenics, Lantheus Holdings completed the acquisition of Progenics by means of a merger of Merger Sub with and into Progenics, with Progenics becoming an indirect subsidiary of Lantheus Holdings following the completion of such merger (the “Progenics Acquisition”).

In connection with the Progenics Acquisition, Lantheus Holdings issued 26,844,877 shares of Lantheus Holdings common stock and 86,630,633 contingent value rights (each a “CVR”) tied to the financial performance of PYLARIFY to former Progenics stockholders and option holders. Each CVR entitled its holder to receive a pro rata share of aggregate cash payments equal to 40% of United States (“U.S.”) net sales generated by PYLARIFY in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively. The Company’s aggregate payments in respect of the CVRs, together with any other non-stock consideration treated as paid in connection with the Progenics Acquisition, was capped at 19.9% of the total consideration the Company paid in the Progenics Acquisition. Based on the Company’s 2022 PYLARIFY net sales, the Company determined that the aggregate payment obligation under the CVRs was $99.6 million, which was the maximum amount payable. The Company paid out this amount in May 2023 in full satisfaction of the CVRs.

The Company has not adopted any new accounting standards during the nine months ended September 30, 2023.

The following table summarizes revenue by revenue source as follows:

________________________________

(1)The Company’s product revenue includes PYLARIFY and DEFINITY among other products. This category represents the delivery of physical goods. The Company applies the same revenue recognition policies and judgments for all its principal products.

(2)The Company recognized $24.0 million license revenue in the first quarter of 2022 related to an agreement with Novartis Pharma AG.

The Company classifies its revenues into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Radiopharmaceutical Oncology includes PYLARIFY and AZEDRA. Precision Diagnostics includes DEFINITY, TechneLite and other diagnostic imaging products. Strategic Partnerships and Other Revenue includes strategic partnerships and other arrangements related to other products of the Company, including our royalty revenue from our license of RELISTOR. On August 2, 2023, the Company sold the right to its RELISTOR net sales royalties, which is classified as a licensed intangible asset (“RELISTOR royalty asset”), under its license agreement with Bausch Health Companies, Inc. (“Bausch”); the Company retained the rights to future sales-based milestone payments.

On January 31, 2022, the Company entered into a global settlement agreement with Novartis Pharma AG (“Novartis”), Advanced Accelerator Applications USA, Inc. (“AAA”), Endocyte, Inc. (“Endocyte”) and their affiliates (the “Novartis Agreement”) to settle certain disputes between the parties. Under the Novartis Agreement, Novartis agreed to make a lump sum payment to the Company, as well as to reimburse the Company for certain fees and expenses in connection with certain litigation, and the Company agreed to license certain intellectual property to Novartis. In addition, the Company agreed to supply PYLARIFY for clinical purposes at an arms-length value which will be recorded revenue in the future as product is provided. In accordance with the Company's ASC 606, Revenue from Contracts with Customers, assessment, Novartis is considered to be a customer. The Company determined that the $24.0 million that Novartis paid to the Company pursuant to the Novartis Agreement constituted a single element which was satisfied on the date of the execution of the Novartis Agreement. The Company determined that the license of intellectual property carried a fair value of $24.0 million. As such, the Company assigned the value of the license to be $24.0 million, which constitutes the entire transaction price and does not require further allocation. The Company determined that the $24.0 million represented the point at which Novartis, as the licensee, was able to use and benefit from the license and recognized revenue when the license was granted to Novartis upon execution of the Novartis Agreement. The Company recognized the $24.0 million fee as revenue on its consolidated statement of operations for the quarter ended March 31, 2022.

Revenue by product category on a net basis is as follows:

The Company would be required to allocate a portion of its revenue received from commercial contracts to future reporting periods to the extent the Company had performance obligations that extended beyond one year. However, the Company’s performance obligations are typically part of contracts that have an original expected duration of one year or less. As such, the Company is not disclosing the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied (or partially satisfied) as of the end of the reporting period.

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability of fair value measurements, financial instruments are categorized based on a hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:

•Level 1 — Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

•Level 2 — Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).

•Level 3 — Unobservable inputs that reflect a Company’s estimates about the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including its own data.

The Company’s financial assets and liabilities measured at fair value on a recurring basis currently consist of money market funds and contingent consideration liabilities. The Company invests excess cash from its operating cash accounts in overnight investments and reflects these amounts in cash and cash equivalents in the condensed consolidated balance sheets at fair value using quoted prices in active markets for identical assets.

The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis:

During the three and nine months ended September 30, 2023, there were no transfers into or out of Level 3.

As part of the Progenics Acquisition, the Company issued CVRs and recorded the fair value as part of consideration transferred. Each CVR entitled its holder to receive a pro rata share of aggregate cash payments equal to 40% of U.S. net sales generated by PYLARIFY in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively, subject to a maximum cap. Refer to Note 1, “Basis of Presentation” for further details on the CVRs. Based on the U.S. net sales generated by PYLARIFY in 2022, the Company paid out the maximum amount payable under the CVRs from available cash in May 2023 in full satisfaction of the CVR obligation.

The Company also assumed contingent consideration liabilities related to a previous acquisition completed by Progenics in 2013 (“2013 Acquisition”). These contingent consideration liabilities include potential payments of up to $70.0 million if the Company attains certain net sales targets primarily for AZEDRA and 1095 (also known as 131 I-MIP-1095) and a $5.0 million 1095 commercialization milestone. Additionally, there is a potential payment of up to $10.0 million related to a 1404 commercialization milestone. The Company’s total potential payments related to the 2013 Acquisition are approximately $85.0 million. The Company considers the contingent consideration liabilities relating to the 2013 Acquisition each a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value of these was determined based on probability adjusted discounted cash flows and Monte Carlo simulation models that included significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs with respect to 1095 and 1404 are the probabilities of achieving regulatory approval of those development projects and subsequent commercial success.

Significant changes in any of the probabilities of success, the probabilities as to the periods in which sales targets and milestones will be achieved, discount rates or underlying revenue forecasts would result in a significantly higher or lower fair value measurement. The Company records the contingent consideration liability at fair value with changes in estimated fair values recorded in general and administrative expenses in the condensed consolidated statements of operations. The Company can give no assurance that the actual amounts paid, if any, in connection with the contingent consideration liabilities, will be consistent with any recurring fair value estimate of such contingent consideration liabilities.

The following tables summarize quantitative information and assumptions pertaining to the fair value measurement of liabilities using Level 3 inputs at September 30, 2023.

For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated:

The change in fair value of the contingent financial liabilities resulted in a reduction of general and administrative expense of $9.5 million for the nine months ended September 30, 2023 and was primarily due to changes in revenue forecasts and the passage of time (excluding the CVRs). The Company made the applicable cash payment related to the CVRs in May 2023.

The Company calculates income taxes at the end of each reporting period based on the estimated effective tax rate for the full year, adjusted for any discrete events which are recorded in the period they occur. Cumulative adjustments to the tax provision are recorded in the reporting period in which a change in the estimated annual effective tax rate is determined. The Company’s income tax expense is presented below:            

The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realizability of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are realizable, the Company evaluated all available evidence, and weighed the objective evidence and expected impact. The Company continues to retain immaterial valuation allowances against the net deferred tax assets of certain of its foreign subsidiaries.

In connection with the Company’s acquisition of the medical imaging business from Bristol-Myers Squibb (“BMS”) in 2008, the Company recorded a liability for uncertain tax positions related to the acquired business and simultaneously entered into a tax indemnification agreement with BMS under which BMS agreed to indemnify the Company for any payments made to settle those uncertain tax positions with the state taxing authorities.

In accordance with the Company’s accounting policy, the change in the tax liabilities, penalties and interest associated with these obligations (net of any offsetting federal or state benefit) is recognized within income tax expense. As these reserves change, adjustments are included in income tax expense while the offsetting adjustment is included in other income. Assuming that the remaining receivable from BMS continues to be considered recoverable by the Company, there will be no effect on net income and no net cash outflows related to these liabilities.

During the third quarter of 2023, the Company entered into a settlement agreement with one state, for which the Company was indemnified pursuant to the tax indemnification agreement, and accordingly reduced the amount of uncertain tax positions by $4.8 million. The Company continues to accrue interest on the outstanding uncertain tax positions.

Inventory consisted of the following:

        

(in thousands)			September 30, 2023						December 31, 2022
Raw materials			$	26,936					$	19,987
Work in process			9,968						8,234
Finished goods			19,558						7,254
Total inventory			$	56,462					$	35,475

    

Inventory costs associated with products that have not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefit of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed during the period the costs are incurred.

The Company has no inventory pending regulatory approval as of September 30, 2023.

Property, plant and equipment, net, consisted of the following:

Depreciation and amortization expense related to property, plant and equipment, net, was $2.9 million and $3.9 million for the three months ended September 30, 2023 and 2022, respectively, and $9.6 million and $10.3 million for the nine months ended September 30, 2023 and 2022, respectively.

During the three months ended June 30, 2023, as a result of a decline in expected future cash flows related to a certain asset group, the Company determined certain impairment triggers had occurred. The Company reviewed revised undiscounted cash flows that were estimated to be generated by the asset group as of June 30, 2023. Based on the undiscounted cash flow analysis, the Company determined that the asset group had net carrying values that exceeded their estimated undiscounted future cash flows. The Company then estimated the fair value of the asset group based on their discounted cash flows. The carrying value exceeded the fair value and as a result, the Company recorded a noncash impairment of $6.0 million for the six months ended June 30, 2023 in cost of goods sold in the condensed consolidated statements of operations.

During the first quarter of 2023, the Company committed to a plan to sell a portion of its land and buildings associated with its Billerica, Massachusetts campus. Effective March 16, 2023, the Company entered into a purchase and sale agreement (the “P&S”) with a prospective buyer. The assets were classified as held for sale and comprised entirely of property, plant and equipment, net. The Company determined that the fair value of the net assets being sold exceeded the carrying value as of September 30, 2023. The purchase price for the campus sale is $10.0 million in cash. The transaction is expected to close during the first half of 2024.

Accrued expenses and other liabilities and other long-term liabilities are comprised of the following:

The Company considers its legal obligation to remediate its facilities upon a potential decommissioning of its radioactive-related operations as an asset retirement obligation. The Company has production facilities which manufacture and process radioactive materials at its North Billerica, Massachusetts and Somerset, New Jersey sites. As of September 30, 2023, the liability is measured at the present value of the obligation expected to be incurred and is approximately $25.1 million.

The following table provides a summary of the changes in the Company’s carrying value of asset retirement obligations:

The Company is required to provide the Massachusetts Department of Public Health and New Jersey Department of Environmental Protection financial assurance demonstrating the Company’s ability to fund the decommissioning of its North Billerica, Massachusetts and Somerset, New Jersey production facilities, respectively, upon closure. The Company has provided this financial assurance in the form of a $30.3 million surety bond.

Intangibles, net, consisted of the following:

The Company recorded amortization expense for its intangible assets of $11.7 million and $8.3 million for the three months ended September 30, 2023 and 2022, respectively, and $35.1 million and $24.9 million for the nine months ended September 30, 2023 and 2022, respectively.

On August 2, 2023, the Company sold the right to its RELISTOR royalty asset under its license agreement with Bausch; the Company retained the rights to future sales-based milestone payments. The Company received an initial payment of approximately $98.0 million in connection with the sale and has the right to receive an additional payment from the buyer of $5.0 million if worldwide net sales of RELISTOR in 2025 exceed a specified threshold. The additional payment would be recognized upon achievement of the specified threshold.

Decreases of $63.6 million of license assets and $17.5 million of associated accumulated amortization, as well as a gain of $51.8 million were recorded as a result of the sale.

In March 2023, the Company stopped all development activities in relation to a future indication associated with AZEDRA, which is classified as an in process research and development (“IPR&D”) intangible asset. The Company did not identify any alternative future uses or development programs for the asset, therefore the asset group, which consists of the IPR&D asset and a currently marketed product, was assessed for impairment as of March 31, 2023. The Company considered several factors including market share, price and competitive product offerings in evaluating the quantitative impact of the future cash flows. The Company concluded that the carrying amount exceeded the fair value of the asset group, which had no value. Accordingly, in the three months ended March 31, 2023, the Company recorded a non-cash impairment charge associated with the IPR&D asset of $15.6 million in research and development expenses and a non-cash impairment charge of $116.4 million in cost of goods sold in the condensed consolidated statements of operations.

On August 15, 2023, the Company announced that it had made the decision to discontinue the production and promotion of AZEDRA and would be winding down its Somerset, New Jersey manufacturing site. The Company currently intends to continue manufacturing AZEDRA into the first quarter of 2024, to the extent feasible, with the goal of providing doses of AZEDRA to current patients so they can complete their treatment regimen.

In February 2023, the Company entered into an agreement with Cerveau to purchase all of the outstanding capital stock of Cerveau for approximately $35.3 million. In May 2023, upon successful completion of a technology transfer, the Company paid $10.0 million to the selling stockholders of Cerveau. This additional contingent payment was capitalized as part of the asset cost and increased the Company’s customer relationship intangible assets. See Note 19, “Acquisition of Assets” for further discussion of the Cerveau acquisition.

The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets:

As of September 30, 2023, the Company’s maturities of principal obligations under its long-term debt and other borrowings are as follows:

In December 2022, the Company refinanced its existing credit facility, consisting of (i) a $200.0 million five-year term loan facility (the “2019 Term Facility”) and (ii) a $200.0 million five-year revolving credit facility (the “2019 Revolving Facility” and, together with the 2019 Term Facility, the “2019 Facility”), with a new $100.0 million delayed draw term loan facility (the “2022 Term Facility” and, the loans thereunder, the “Term Loans”) and a new $350.0 million five-year revolving credit facility (the “2022 Revolving Facility” and, together with the 2022 Term Facility, the “2022 Facility”).

The Company used approximately $7.8 million of cash on hand to primarily repay the principal amount of the loans outstanding related to the 2019 Facility through the nine months ended September 30, 2022. In addition, in December 2022, the Company used approximately $167.6 million of cash on hand to repay in full the aggregate remaining principal amount of the loans outstanding under the 2019 Facility and to pay related interest, transaction fees and expenses.

The Company paid off the 2019 Term Facility using available cash and did not utilize another term loan to fund the payoff. While the 2022 Term Facility allowed for a delayed draw term loan, the loan was not drawn upon. The Company recorded a loss on extinguishment of debt of $0.6 million related to the write-off of unamortized debt issuance costs and debt discounts associated with the 2019 Term Facility. In addition, the Company incurred and capitalized $2.7 million of new deferred financing costs related to the refinancing.

Under the terms of the 2022 Revolving Facility, the lenders are committed to extending credit to the Company from time to time until December 2, 2027 consisting of revolving loans (the “Revolving Loans”) in an aggregate principal amount not to exceed $350.0 million (the “Revolving Commitment”) at any time, including a $20.0 million sub-facility for the issuance of letters of credit (the “Letters of Credit”) and a $10.0 million sub-facility for swingline loans (the “Swingline Loans”). The Revolving Loans, Letters of Credit, and the Swingline Loans, if used, are expected to be used for working capital and for other general corporate purposes.

The Revolving Loans bear interest, with pricing based from time to time at the Company’s election, at (i) the secured overnight financing rate as published by the Federal Reserve Bank of New York on its website plus an applicable margin that ranges from 1.50% to 2.50% based on the Company’s total net leverage ratio or (ii) the alternative base rate plus an applicable margin that ranges from 0.50% to 1.50% based on the Company’s total net leverage ratio. The 2022 Revolving Facility also includes an unused commitment fee at a rate ranging from 0.15% to 0.35% per annum based on the Company’s total net leverage ratio.

The Company is permitted to voluntarily prepay the Revolving Loans, in whole or in part, or reduce or terminate the Revolving Commitment, in each case, without premium or penalty. On any business day on which the total amount of outstanding Revolving Loans, Letters of Credit and Swingline Loans exceeds the total Revolving Commitment, the Company must prepay the Revolving Loans in an amount equal to such excess. The Company is not required to make mandatory prepayments under the 2022 Revolving Facility. As of September 30, 2023, there were no outstanding borrowings under the 2022 Revolving Facility.

The Company has the right to request an increase to the Revolving Commitment in an aggregate principal amount of up to the sum of $335.0 million or consolidated EBITDA for the four consecutive fiscal quarters most recently ended, plus additional amounts in certain circumstances (collectively, the “Incremental Cap”), minus certain incremental term loans made pursuant to specified incremental term loan commitments (“Incremental Term Loans”). The Company has the right to request Incremental Term Loans in an aggregate principal amount of up to the Incremental Cap less any incremental increases to the Revolving Commitment. Proceeds of Incremental Term Loans may be used for working capital and for other general corporate purposes and will bear interest at rates agreed between the Company and the lenders providing the Incremental Term Loans.

The 2022 Facility contains a number of affirmative, negative and reporting covenants, as well as financial maintenance covenants pursuant to which the Company is required to be in quarterly compliance, measured on a trailing four quarter basis, with two financial covenants. The minimum interest coverage ratio, commencing with the fiscal quarter ended December 31, 2022, must be at least 3.00 to 1.00. The maximum total net leverage ratio permitted by the financial covenant is displayed in the table below:

The 2022 Facility contains usual and customary restrictions on the ability of the Company and its subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell or otherwise dispose of all or substantially all of its assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates.

Upon an event of default, the Administrative Agent will have the right to declare the loans and other obligations outstanding under the 2022 Facility immediately due and payable and all commitments immediately terminated.

The 2022 Facility is guaranteed by Lantheus Holdings, and certain subsidiaries of LMI, including Progenics and Lantheus Real Estate, and obligations under the 2022 Facility are generally secured by first priority liens over substantially all of the assets of each of LMI, Lantheus Holdings, and certain subsidiaries of LMI, including Progenics and Lantheus Real Estate (subject to customary exclusions set forth in the transaction documents) owned as of December 2, 2022 or thereafter acquired.

On December 8, 2022, the Company issued $575.0 million in aggregate principal amount of 2.625% Convertible Senior Notes due 2027 (the “Notes”), which includes $75.0 million in aggregate principal amount of Notes sold pursuant to the full exercise of the initial purchasers’ option to purchase additional Notes. The Notes were issued under an indenture, dated as of December 8, 2022 (the “Indenture”), among the Company, LMI (the “Guarantor”), as Guarantor, and U.S. Bank Trust Company, National Association, as Trustee. The net proceeds from the issuance of the Notes were approximately $557.8 million after deducting the initial purchasers’ discounts and offering expenses payable by the Company.

The Notes are senior unsecured obligations of the Company. The Notes are fully and unconditionally guaranteed on a senior unsecured basis by the Guarantor. The Notes bear interest at a rate of 2.625% per year, payable semi-annually in arrears on June 15 and December 15 of each year, beginning on June 15, 2023, and will mature on December 15, 2027 unless earlier redeemed, repurchased or converted in accordance with their terms. The initial conversion rate for the Notes is 12.5291 shares of the Company’s common stock per $1,000 in principal amount of Notes (which is equivalent to an initial conversion price of approximately $79.81 per share of the Company’s common stock, representing an initial conversion premium of approximately 42.5% above the closing price of $56.01 per share of the Company’s common stock on December 5, 2022). In no event shall the conversion rate per $1,000 in principal amount of notes exceed 17.8539 shares of the Company’s common stock. Prior to the close of business on the business day immediately preceding September 15, 2027, the Notes may be converted at the option of the holders only upon occurrence of specified events and during certain periods, and thereafter until the close of business on the business day immediately preceding the maturity date, the Notes may be converted at any time. The Company will satisfy any conversion by paying cash up to the aggregate principal amount of the Notes to be converted and by paying or delivering, as the case may be, cash, shares of the Company’s common stock, or a combination of cash and shares of the Company’s common stock, at its election, in respect of the remainder, if any, of its conversion obligation in excess of the aggregate principal amount of the Notes being converted. The Company may redeem for cash all or any portion of the Notes, at its option, on or after December 22, 2025 if the closing sale price per share of the Company’s common stock exceeds 130% of the conversion price of the Notes for a specified period of time. The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

The Company evaluated the Notes upon completion of the sale and concluded on the following features:

•Conversion Feature: The Company determined that the conversion feature qualifies for the classification of equity. As a result, the conversion feature should not be bifurcated as a derivative instrument and the Notes were accounted for as a single liability.

•Redemption Features: The redemption features were reviewed within the Notes and the Company determined that the redemption features are closely related to the Notes and as such should not be separately accounted for as a bifurcated derivative instrument.

•Additional Interest Features: The Notes may result in additional interest if the Company fails to timely file any document that the Company is required to file with the SEC pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The Company will pay additional interest on the notes at a rate equal to 0.25% to 0.50% per annum based on the principal amount of notes outstanding for each day the Company failure to file has occurred or the notes are not otherwise freely tradable. Further, if the notes are assigned a restricted CUSIP number or the notes are not otherwise freely tradable pursuant to Rule 144 under the Securities Act by holders other than our affiliates or holders that were our affiliates at any time during the three months immediately preceding as of the 385th day after the last date of original issuance of the notes offered hereby, the Company will pay additional interest on the notes at a rate equal to (i) 0.25% to 0.50% per annum based on the principal amount of notes outstanding for each day until the restrictive legend has been removed from the notes, the notes are assigned an unrestricted CUSIP and the notes are freely tradable. The Company concluded that the interest feature is unrelated to the credit risk and should be bifurcated from the Notes, however, the Company assessed the probabilities of triggering events occurring under these features and does not expect to trigger the aforementioned events. These events will continue to be monitored to determine whether the interest feature will be bifurcated if it has value.

As of September 30, 2023, the carrying value of the Notes was $575.0 million and the fair value of the liability was $575.0 million. The Company recorded interest expense of approximately $3.9 million and $11.8 million related to the Notes for the three and nine months ended September 30, 2023, respectively. There were no conversions of Notes during the nine months ended September 30, 2023.

The Company has used, but does not currently use, interest rate swaps to reduce the variability in cash flows associated with portions of the Company’s interest payments on variable rate debt. In March 2020, the Company entered into interest rate swap contracts to fix the LIBOR rate on a notional amount of $100.0 million through May 31, 2024. The average fixed LIBOR rate on the interest rate swaps was approximately 0.82%. This agreement involved the receipt of floating rate amounts in exchange for fixed rate interest payments over the life of the agreement without an exchange of the underlying principal amount. The interest rate swaps were designated as cash flow hedges. In accordance with hedge accounting, the interest rate swaps were recorded on the Company’s consolidated balance sheets at fair value, and changes in the fair value of the swap agreements were recorded to other comprehensive loss and reclassified to interest expense in the period during which the hedged transaction affected earnings or it will become probable that the forecasted transaction would not occur.

On December 2, 2022, the Company voluntarily terminated the interest rate swap contracts in connection with the refinancing of debt. Upon termination, the Company received approximately $5.6 million in cash and the remaining balance of approximately $5.5 million in accumulated other comprehensive income related to the interest rate swap contracts were reclassified into earnings.

The components of accumulated other comprehensive (loss) income, net of tax of zero and $1.5 million for the nine months ended September 30, 2023 and 2022, respectively, consisted of the following:

The following table presents stock-based compensation expense recognized in the Company’s accompanying condensed consolidated statements of operations: